Overview

Management of Insomnia in Breast Cancer Patients

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
To provide preliminary data on the effects of brief behavioral therapy for insomnia (BBT-I) on insomnia in breast cancer patients expecting to receive cancer treatment (unspecified). Participants will be randomized into 4 groups: - Arm 1: Brief Behavioral Treatment of Insomnia (BBT-I) + Armodafinil 150 mg/day. - Arm 2: Behavioral therapy for insomnia (CBT-I) + Armodafinil 150 mg/day. - Arm 3: Brief Behavioral Treatment of Insomnia (BBT-I) without pharmaceutical intervention. - Arm 4: Behavioral therapy for insomnia (CBT-I) without pharmaceutical intervention.
Phase:
Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
National Cancer Institute (NCI)
Treatments:
Armodafinil
Modafinil